Literature DB >> 7527779

Technetium-99m sestamibi: an indicator of breast cancer invasiveness.

F Scopinaro1, O Schillaci, M Scarpini, P L Mingazzini, L Di Macio, M Banci, R Danieli, M Zerilli, M R Limiti, A Centi Colella.   

Abstract

As recently shown, angiogenesis is the most reliable marker of breast cancer invasiveness. Unfortunately it must be assessed by immunohistochemistry on tissue specimens. We have used technetium-99m sestamibi, a marker of regional blood flow in other organs that often but not always images breast cancer, to assess the invasiveness of this tumour. Nineteen patients, ten with nodal metastases and nine without any metastases, were studied with 99mTc-sestamibi scintigraphy before operation. Angiogenesis was quantitatively assessed by immunohistochemical staining of endothelia for factor VIII. All the node-positive (N+) patients at surgical revision showed a positive 99mTc-sestamibi scan of the primary tumour and all the N-patients were negative. Nine out of ten N+ and sestamibi-positive tumours showed more than 135 microvessels/mm2 and one showed 99 microvessels/mm2; by contrast there were 71.6 +/- 12.1 microvessels/mm2 in the nine N- and sestamibi-negative tumours. Our study suggests that 99mTc-sestamibi is a marker of breast cancer invasiveness: its uptake is related to angiogenesis and, possibly, to oxidative metabolism of the tumour.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7527779     DOI: 10.1007/bf00238124

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  8 in total

1.  The prospects for imaging lymph nodes in breast cancer.

Authors:  S M Allan
Journal:  Eur J Nucl Med       Date:  1992

2.  Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro.

Authors:  L I Delmon-Moingeon; D Piwnica-Worms; A D Van den Abbeele; B L Holman; A Davison; A G Jones
Journal:  Cancer Res       Date:  1990-04-01       Impact factor: 12.701

Review 3.  Metastasis and angiogenesis.

Authors:  V Mahadevan; I R Hart
Journal:  Acta Oncol       Date:  1990       Impact factor: 4.089

4.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.

Authors:  N Weidner; J P Semple; W R Welch; J Folkman
Journal:  N Engl J Med       Date:  1991-01-03       Impact factor: 91.245

5.  Lack of correlation between tritiated deoxyglucose, thallium-201 and technetium-99m-MIBI cell incorporation under various cell stresses.

Authors:  D O Slosman; J Pugin
Journal:  J Nucl Med       Date:  1994-01       Impact factor: 10.057

Review 6.  The EGF receptor system as a target for antitumor therapy.

Authors:  B W Ennis; M E Lippman; R B Dickson
Journal:  Cancer Invest       Date:  1991       Impact factor: 2.176

7.  Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer.

Authors:  E R Horak; R Leek; N Klenk; S LeJeune; K Smith; N Stuart; M Greenall; K Stepniewska; A L Harris
Journal:  Lancet       Date:  1992-11-07       Impact factor: 79.321

8.  Effect of mitochondrial viability and metabolism on technetium-99m-sestamibi myocardial retention.

Authors:  P Crane; R Laliberté; S Heminway; M Thoolen; C Orlandi
Journal:  Eur J Nucl Med       Date:  1993-01
  8 in total
  19 in total

1.  Characterizing the contribution of cardiac and hepatic uptake in dedicated breast SPECT using tilted trajectories.

Authors:  K L Perez; S J Cutler; P Madhav; M P Tornai
Journal:  Phys Med Biol       Date:  2010-07-30       Impact factor: 3.609

2.  Usefulness of feature analysis of breast-specific gamma imaging for predicting malignancy.

Authors:  Eun Kyoung Choi; Jooyeon Jamie Im; Chang Suk Park; Yong-An Chung; Kijun Kim; Jin Kyoung Oh
Journal:  Eur Radiol       Date:  2018-06-12       Impact factor: 5.315

3.  The use of technetium-99m sestamibi to indicate breast cancer invasiveness.

Authors:  P Bourgeois
Journal:  Eur J Nucl Med       Date:  1995-06

4.  Effect of menstrual cycle phase on background parenchymal uptake at molecular breast imaging.

Authors:  Carrie B Hruska; Amy Lynn Conners; Celine M Vachon; Michael K O'Connor; Lynne T Shuster; Adam C Bartley; Deborah J Rhodes
Journal:  Acad Radiol       Date:  2015-06-22       Impact factor: 3.173

5.  Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression.

Authors:  J L Moretti; H Azaloux; D Boisseron; J C Kouyoumdjian; J Vilcoq
Journal:  Eur J Nucl Med       Date:  1996-08

6.  Scintimammography with technetium-99m tetrofosmin in the diagnosis of breast cancer and lymph node metastases.

Authors:  L Mansi; P F Rambaldi; E Procaccini; F D Gregorio; A Laprovitera; B Pecori; W D Vecchio
Journal:  Eur J Nucl Med       Date:  1996-08

7.  Breast scintigraphy today: indications and limitations.

Authors:  Orazio Schillaci; John R Buscombe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-23       Impact factor: 9.236

Review 8.  99mTc-MIBI in the evaluation of breast cancer biology.

Authors:  Silvana Del Vecchio; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-23       Impact factor: 9.236

9.  A (99m)Tc-labeled triphenylphosphonium derivative for the early detection of breast tumors.

Authors:  Zhixin Li; Marcos Lopez; Micaël Hardy; Donna M McAllister; Balaraman Kalyanaraman; Ming Zhao
Journal:  Cancer Biother Radiopharm       Date:  2009-10       Impact factor: 3.099

10.  Diagnostic Performance of Breast-Specific Gamma Imaging (BSGI) for Breast Cancer: Usefulness of Dual-Phase Imaging with (99m)Tc-sestamibi.

Authors:  Ji Sun Park; Ah Young Lee; Kyung Pyo Jung; Su Jung Choi; Seok Mo Lee; Sang Kyun Bae
Journal:  Nucl Med Mol Imaging       Date:  2012-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.